Stay updated on Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page.

Latest updates to the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page
- Check6 days agoChange Detected- The institution name was updated from UT Southwestern Medical Center to University of Texas Southwestern Medical Center.SummaryDifference0.1%

- Check13 days agoChange DetectedLocations information was added (including Texas) and the page was updated to revision v3.3.3, while the Texas Locations entry and the HHS Vulnerability Disclosure were removed.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedRevision: v3.3.2 is now displayed, replacing the previous Revision: v3.2.0.SummaryDifference0.1%

- Check48 days agoChange DetectedThe notice about potential delays in updates due to a lapse in government funding was removed. This reduces visibility into the page's current operating status and data currency.SummaryDifference0.4%

- Check63 days agoChange DetectedThe new screenshot shows minor cosmetic/layout changes to the page; no study data or eligibility criteria changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check91 days agoChange DetectedUpdated version to v3.2.0 and added a government-operating-status notice; removed the prior v3.1.0 tag.SummaryDifference2%

Stay in the know with updates to Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page.